In vitro–in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine
Version of Record online: 11 NOV 2002
British Journal of Clinical Pharmacology
Volume 54, Issue 5, pages 493–503, November 2002
How to Cite
Boase, S. and Miners, J. O. (2002), In vitro–in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine. British Journal of Clinical Pharmacology, 54: 493–503. doi: 10.1046/j.1365-2125.2002.01669.x
- Issue online: 11 NOV 2002
- Version of Record online: 11 NOV 2002
- Accepted 22 July 2002.
- in vitro-in vivo correlation;
Aims To investigate the effects of incubation conditions on the kinetic constants for zidovudine (AZT) glucuronidation by human liver microsomes, and whether microsomal intrinsic clearance (CLint) derived for the various conditions predicted hepatic AZT clearance by glucuronidation (CLH) in vivo.
Methods The effects of incubation constituents, particularly buffer type (phosphate, Tris) and activators (Brij58, alamethacin, UDP-N-acetylglucosamine (UDP-NAcG)), on the kinetics of AZT glucuronidation by human liver microsomes was investigated. AZT glucuronide (AZTG) formation by microsomal incubations was quantified by h.p.l.c. Microsomal CLint values determined for the various experimental conditions were extrapolated to a whole organ CLint and these data were used to calculate in vivo CLH using the well-stirred, parallel tube and dispersion models.
Results Mean CLint values for Brij58 activated microsomes in both phosphate (3.66 ± 1.40 µl min−1 mg−1, 95% CI 1.92, 5.39) and Tris (3.79 ± 0.74 µl min−1 mg−1, 95% CI 2.87, 4.71) buffers were higher (P < 0.05) than the respective values for native microsomes (1.04 ± 0.42, 95% CI 0.53, 1.56 and 1.37 ± 0.30 µl min−1 mg−1, 95% CI 1.00, 1.73). Extrapolation of the microsomal data to a whole organ CLint and substitution of these values in the expressions for the well-stirred, parallel tube and dispersion models underestimated the known in vivo blood AZT clearance by glucuronidation by 6.5- to 23-fold (3.61–12.71 l h−1vs 82 l h−1). There was no significant difference in the CLH predicted by each of the models for each set of conditions. A wide range of incubation constituents and conditions were subsequently investigated to assess their effects on GAZT formation, including alamethacin, UDP-NAcG, MgCl2, d-saccharic acid 1,4-lactone, ATP, GTP, and buffer pH and ionic strength. Of these, only decreasing the phosphate buffer concentration from 0.1 m to 0.02 m for Brij58 activated microsomes substantially increased the rate of GAZT formation, but the extrapolated CLH determined for this condition still underestimated known AZT glucuronidation clearance by more than 4-fold. AZT was shown not to bind nonspecifically to microsomes. Analysis of published data for other glucuronidated drugs confirmed a trend for microsomal CLint to underestimate in vivo CLH.
Conclusions AZT glucuronidation kinetics by human liver microsomes are markedly dependent on incubation conditions, and there is a need for interlaboratory standardization. Extrapolation of in vitro CLint underestimates in vivo hepatic clearance of drugs eliminated by glucuronidation.